RACK1 and gastric cancer: Taken together, UBE2T-mediated RACK1 degradation drives GC progression through the nuclear accumulation of β-catenin and Wnt/β-catenin signaling hyperactivation, suggesting that RACK1 upstream regulator UBE2T functions as a potential target for GC therapy.